Please check your internet connection and try again.
# Mylotarg (gemtuzumab ozogamicin)
## Overview
Mylotarg is a CD33-directed antibody-drug conjugate. It consists of a humanized anti-CD33 monoclonal antibody covalently linked to the cytotoxic agent calicheamicin.
## Primary Indications
* Newly diagnosed CD33-positive acute myeloid leukemia (AML) in adults and pediatric patients aged 1 month and older.
* Relapsed or refractory CD33-positive AML in adults and pediatric patients aged 2 years and older.
## Adult Dosing
* **Newly diagnosed AML:** 3 mg/m² (up to a maximum dose of 4.5 mg per single dose) on days 1, 4, and 7 in combination with daunorubicin and cytarabine.
* **Relapsed/Refractory AML:** 3 mg/m² (up to a maximum dose of 4.5 mg per single dose) on days 1, 4, and 7 as a single agent.
* *Note: Dosing depends on local protocols and chemotherapy backbone; verify specific combination regimens.*
## Pediatric Dosing
* **Newly diagnosed AML:** 3 mg/m² (up to a maximum dose of 4.5 mg) on days 1, 4, and 7. For patients with a body surface area (BSA) <0.6 m², the dose is 0.1 mg/kg.
* **Relapsed/Refractory AML:** 3 mg/m² (up to a maximum dose of 4.5 mg) on days 1, 4, and 7. For patients with a BSA <0.6 m², the dose is 0.1 mg/kg.
## Dose Adjustments
* **Hepatic Impairment:** Avoid in patients with severe hepatic impairment (Total Bilirubin >2x ULN; AST/ALT >2.5x ULN).
* **Infusion Reactions:** Interrupt infusion if mild-to-moderate symptoms occur. If severe, discontinue permanently.
* **Hepatotoxicity/VOD:** Permanently discontinue for signs of veno-occlusive disease (VOD)/sinusoidal obstruction syndrome (SOS).
## Contraindications
* Hypersensitivity to the active substance or any excipients.
* Prior severe or life-threatening hypersensitivity to gemtuzumab ozogamicin.
## Adverse Effects
* **Hepatotoxicity:** Including veno-occlusive disease (VOD/SOS), elevated transaminases, and bilirubin.
* **Infusion-Related Reactions:** Chills, fever, hypotension, dyspnea.
* **Myelosuppression:** Prolonged neutropenia, thrombocytopenia, and anemia.
* **Infections:** Increased risk due to profound immunosuppression.
* **Hemorrhage:** Associated with thrombocytopenia.
## Key Drug Interactions
* **Hepatotoxic Agents:** Risk of additive hepatotoxicity; use with extreme caution.
* **Strong CYP3A4 Inhibitors/Inducers:** Theoretically affect the conjugated calicheamicin, though clinical significance in the context of the ADC structure is limited. Use caution when co-administering potent agents.
## Monitoring
* **Liver Function:** Baseline and prior to each dose (ALT, AST, Total Bilirubin, Alkaline Phosphatase). Monitor closely for signs/symptoms of VOD/SOS (weight gain, hepatomegaly, ascites).
* **Hematology:** Frequent CBCs to monitor for cytopenias and recovery.
* **Infection:** Monitor for signs of systemic infection or fever.
* **Cardiac:** Baseline/periodic ECG if patient is receiving cumulative anthracycline therapy.
## Clinical Pearls
* **VOD Risk:** The risk of VOD is specifically increased in patients undergoing hematopoietic stem cell transplantation (HSCT) after Mylotarg, particularly if the conditioning regimen contains hepatotoxic agents.
* **Premedication:** Always administer corticosteroids, an antihistamine, and an antipyretic 1 hour prior to dosing to minimize infusion-related reactions.
* **Handling:** Must be protected from light and prepared using specific handling procedures for cytotoxic agents. Once reconstituted and diluted, it must be administered immediately or stored under specific refrigerated conditions.
***
*Disclaimer: This information is for educational purposes only. Mylotarg dosing and administration protocols are highly specialized. Always verify current prescribing information, institutional protocols, and specific clinical trial guidelines before ordering or administering this medication.*
